+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Thrombosis Drugs Market - Growth, Trends, and Forecasts (2020 - 2025)

  • PDF Icon


  • 111 Pages
  • June 2020
  • Region: Global
  • Mordor Intelligence
  • ID: 4622418
As per the publication of the US Census Bureau in 2018, the population of people aged 65 and above in the United States may increase drastically between 2016 and 2060 period. By 2030, one in five US citizens is expected to be 65 years and older, crossing 78.0 million. Also, according to the National Health and Nutrition Examination Survey (NHANES) conducted in 2013-2014, one in every three adults were considered overweight, and about one in thirteen adults were suffering from extreme obesity. The increasing burden of obesity has also changed significantly in the last one decade, globally. Both developed and emerging markets are having significant issues in controlling the associated diseases. The growing consumption of alcohol and tobacco, with overweight and obesity, adds a high risk of developing significant high blood pressure on veins for a large period of life leading to several thrombosis related complications, thus driving this market. Other factors contributing to the growth of this market are increasing the burden of cardiovascular and trauma cases, with the increasing R&D expenditure in the field of hematological disorders.

In treatment by anti-clotting medication, a patient’s blood takes much longer to clot, such as in case of any accidental cuts. Uncontrolled bleeding is a very common side effect of thrombolytic drugs. Another noteworthy side effect of anticoagulants is a stroke. These side effects of thrombosis drugs often demand alternative therapy recommended by doctors to the patients. Thus, it is among the major barrier for the growth of this market over the forecast period. Another factor that may impede the market growth is lack of awareness about the severity of thrombosis.

Key Market Trends

Factor Xa Inhibitor Segment is Expected to Register a Significant Growth during the Forecast Years

By drug class, the market has been segmented into factor Xa inhibitor, heparin, P2Y12 platelet inhibitor, and other drug classes. The factor Xa inhibitor is expected to grow during the forecast period, due to the high preference of anti-coagulant drugs. These drugs are basically used for the prevention and treatment of pulmonary embolism and deep vein thrombosis. In addition, increasing focus on the development of low-cost drugs and large patient pool contributes to the growth of thrombosis drugs market.

North America Leads the Thrombosis Drugs Market

North America leads the market, owing to the high prevalence of cardiovascular diseases, the upsurge in the demand for progressive treatment options, early adoption of new technologies, and an increase in the elderly population. Europe and the Asia-Pacific are followed next after North America, owing to the presence of a diversified patient pool, emerging economies, and rise in collaboration of domestic and international companies with campaigns for awareness campaign in these regions, thus driving this market.

Competitive Landscape

The thrombosis drugs market is moderately competitive and many of the global players are into the market. For instance, Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb, Johnson & Johnson, Sanofi, Pfizer, Inc., etc. are providing these products across the world.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

This product will be delivered within 2 business days.

Table of Contents

1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Geriatric and Obese Population
4.2.2 Increasing Burden of Cardiovascular and Trauma Cases
4.2.3 Increasing Technological Advancements in Hematology
4.3 Market Restraints
4.3.1 Lack of Awareness about Venous Thromboembolism Conditions
4.3.2 Side Effects Caused, due to Thrombosis Drugs
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5.1 By Drug Class
5.1.1 Factor Xa Inhibitor
5.1.2 Heparin
5.1.3 P2Y12 Platelet Inhibitor
5.1.4 Other Drug Classes
5.2 By Disease Type
5.2.1 Pulmonary Embolism
5.2.2 Atrial Fibrillation
5.2.3 Deep Vein Thrombosis
5.2.4 Other Disease Types
5.3 By Distribution Channel
5.3.1 Hospital Pharmacies
5.3.2 Retail Pharmacies
5.3.3 Online Pharmacies
5.4 Geography
5.4.1 North America United States Canada Mexico
5.4.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.4.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.4.4 Middle East & Africa GCC South Africa Rest of Middle East & Africa
5.4.5 South America Brazil Argentina Rest of South America
6.1 Company Profiles
6.1.1 Aspen Pharmacare Holdings Limited
6.1.2 AstraZeneca PLC
6.1.3 Bayer AG
6.1.4 Boehringer Ingelheim GmbH
6.1.5 Bristol-Myers Squibb
6.1.6 Johnson & Johnson
6.1.7 Pfizer Inc.
6.1.8 Sanofi SA

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Aspen Pharmacare Holdings Limited
  • AstraZeneca PLC
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb
  • Johnson & Johnson
  • Pfizer Inc.
  • Sanofi SA